VEGF trap continues to impress

Article

The Phase II extension study of VEGF Trap-Eye for wet age-related macular degeneration (AMD) has demonstrated extremely favourable results in relation to the primary and key secondary endpoints at the 12-week time point.

The Phase II extension study of VEGF Trap-Eye for wet age-related macular degeneration (AMD) has demonstrated extremely favourable results in relation to the primary and key secondary endpoints at the 12-week time point, according to a statement released by Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG.

Study subjects (n=157) have been receiving the drug - initially on a fixed-dose and then on a PRN (as-needed) dosing schedule - for 52 weeks. The double-masked, prospective, randomized, multicentre Phase II extension study, from which these 12-week results were taken, is to monitor safety, retinal thickness and vision gain. Subjects were separated into groups receiving doses of 0.5 mg at weeks 0, four, eight and 12; doses of 2.0 mg at weeks 0, four, eight and 12; doses of 0.5 mg at baseline and week 12; doses of 2.0 mg at baseline and week 12; and doses of 4.0 mg at baseline and week 12.

In the 2.0 mg fixed-dose followed by PRN dosing groups, subjects achieved a mean improvement in visual acuity from baseline of 9.0 letters, and retinal thickness decreased by a mean 143 µm. In the 0.5 mg fixed-dose followed by PRN dosing groups, subjects achieved a mean improvement in visual acuity from baseline of 5.4 letters, and retinal thickness decreased by a mean 125 µm. At the 52-week follow-up examination, mean visual acuity had increased by 5.3 letters and retinal thickness had decreased by 130 µm from baseline across all dosing groups. No drug-related serious adverse events were noted; the most common adverse events in this group were those typically associated with intravitreal injections.

A full analysis of the 52-week results of the Phase II trial is to be presented at the Retina Society's 2008 meeting, to be held on September 26–28, 2008 in Scottsdale, Arizona, US.

The Phase III trial of the VEGF Trap-Eye, initiated in August 2007, compares VEGF Trap-Eye with Lucentis (ranibizumab; Novartis). The trial is being conducted in the US, Canada, Europe, Asia Pacific, Japan and Latin America, and is currently enrolling patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.